Atrial Fibrillation
Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
Published in Medical Letter on the CDC and FDA, June 1st, 2008
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced that findings from the landmark ATHENA study showed Multaq(R) (dronedarone), a potential therapy for the treatment of patients with atrial fibrillation or atrial flutter, decreased the risk of cardiovascular hospitalizations or death from any cause by a statistically significant 24% (p=3D0.00000002), meeting the study primary endpoint. The ATHENA results will be presented at the late breaking clinical trial session of Heart Rhythm 2008, the Heart Rhythm Society's 29th Annual Scientific Sessions in San Francisco, USA.
For the first time in twenty years of clinical drug trials in atrial fibrillation, an...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Alcoholism
Naltrexone is effective for Alaska Natives and other Alaskans living in rural areas - DOE/Brookhaven National Laboratory
Scientists determine drug target for the most potent botulinum neurotoxin - University of Pittsburgh Schools of the Health Sciences
Most effective initial therapy for HIV-1 infection identified - Acute Myeloid Leukemia
Research on acute myeloid leukemia reported by D. Mulford et al - Alzheimer Disease
Data on Alzheimer disease discussed by researchers at University of Arkansas - Artes Medical, Inc.
Artes Medical Reports Strong Consumer Interest, Rapid Patient Enrollment and Positive Feedback in Largest U.S. Dermal Filler Clinical Study - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
